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Guest Editorial
Direct-to-Consumer Genetic Testing
Two Sides of the Coin
The complete sequencing of the human genome in 2003
was highly publicized; however, many people misinter-
preted that milestone as the “complete understanding of
everything in the human genome.” In actuality, our profes-
sional community’s great progress in molecular diagnostics
has been tempered by the reality that we still have much to
learn about the relationships between genes and disease.
Recently, a set of commentaries in the New England Journal
of Medicine reiterated just how elusive genotype/phenotype
correlations, when applied to complex diseases, can be.1–3
Information culled from such genome-wide association
studies is often repackaged using standard molecular di-
agnostic lab techniques, co-opted by direct-to-consumer
(DTC) genomic testing companies, and sold to consumers.
Is that information of value to the “patient” or is it merely
recreational genomics?
Amid the seemingly incongruent mix of mature and
clinically useful tests for some diseases and paucity of
knowledge for others, DTC genomic testing companies
have come to market offering testing for genetic markers
for health and risk assessment. Certainly we can agree
that people should be proactive in making their own
health care decisions and have a right to information
about their individual genomes; yet, the question remains
whether DTC genomic tests are beneficial in making
those decisions.
As with any retail commercial offering, there are differ-
ent types of DTC genomic testing. One example is testing
directed toward an individual with a family member af-
fected by a specific disease, prompting worry of inherit-
ing the same disease. An Internet search may uncover a
laboratory that offers testing for that mutation without a
doctor’s order. Whether the result is positive or negative
has all manner of interpretation ramifications. Without a
physician and/or (better yet) a genetic counselor in the
mix to aid in interpretation, how useful to the lay “patient”
is the test result?
There’s another type of DTC genomic testing that is
equivalent to genetic fortune telling. Several companies
now offer DNA analysis with a variety of claims ranging
from determining ancestry to choosing cosmetics based
on DNA sequence (the former is possible, but not the
latter). These examples are fairly harmless, and if people
choose to spend their money for these purposes, that’s
their prerogative. Indeed, some have termed this “recre-
ational genomics,” and if one accepts that moniker, then
caveat emptor. But what about companies that make
broad claims regarding genetics and health? That’s more
serious than whether one is descendant from royalty or
has a skin DNA pattern that demands a certain moisturizer.
DTC for Specific Genes
The Internet provides easy access to information about
diseases, which is, for the most part, a good thing. Some
sites are peer-reviewed, frequently updated, and provide
excellent information about diseases and diagnostics
tests, eg, www.labtestsonline.org, www.WebMD.com. On
the other hand, a University of Michigan study found that
the information on Internet sites offering melanoma edu-
cation contained wrong (14%), missing (62%), or misin-
terpreted (41%) information.4 If a patient has the misfor-
tune of “Googling” the “wrong” site, they may not be able
to overcome such an initial handicap. A motivated mela-
noma patient will likely find his or her way to good infor-
mation eventually. It is questionable, however, whether
people can ultimately come to the right conclusions re-
garding more complex genetic health information. The
tests themselves can be imperfect, ie, not detect all pos-
sible mutations, the results can be subtle and/or difficult
to interpret, and risk analysis may be taken out of pro-
portion. Professional counsel is essential in the context of
such examples. Further, the ability to interpret posted or
referenced primary scientific data accurately and cor-
rectly is not within the skill set of most “surfing the Web.”
Whatever the motivation, even if an individual is well
informed before considering or ordering a DTC genomic
test, this is no guarantee that the individual can ade-
quately understand the results for which they may pay
hundreds or thousands of dollars. There are questions we
in the molecular diagnostics community understand can
have complicated answers: (i) what if the test result is
negative and the patient develops symptoms anyway; (ii)
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what if there are other disease-associated genes or mu-
tations not included in the ordered test; (iii) what if the test
was performed incorrectly or performed in an unaccred-
ited, uncertified lab; (iv) what if other factors play a role in
disease development? These questions have complex
answers; while the patient has the right to gain access to
this information via DTC genomic testing, s/he may be
doing themselves and their family members a disservice
by acting in the absence of a physician’s or genetics
professional’s input.
The Internet has marginalized the stock broker and the
travel agent; in the same vein, patients from Gen X and Y
to Baby Boomers can and do gather genetic/medical
information about themselves that may prove useful to the
physician who cares for them. Good quality information
from empowered knowledgeable patients should be wel-
comed by the physician. Appropriate management and
potential intervention, screening, or prophylaxis can be
practiced by the physician for the patient with a delete-
rious mutation in, for example Factor V Leiden or BRCA1.
(It’s only been a year since the Genetic Information Non-
discrimination Act was signed into law; thus, it seems
reasonable to assume that while instances of a patient
bringing such information to the physician, as opposed to
the usual paradigm of the physician ordering the test and
informing the patient, are on the increase, this is anec-
dotal and speculative on our part.) The patient may thus
act as their own health advocate by independently seek-
ing genetic health information that can further aid the
physician. It seems obvious, yet important, to add that
the lay “consumer” of genetic testing results must share
the information and its source with his/her physician. The
physician retains his/her position as the pivotal gate-
keeper of health management and so in that sense, in-
formation obtained via DTC genomic testing challenges
the physician to assimilate and use the information cor-
rectly. One wonders, however, how busy primary care
physicians are themselves able to assess the quality of
genetic lab testing and the nuances of interpreting results.
DTC as Genetic Fortune Telling
As scientists, we know that some diseases arise from a
clearly associated mutation, but most diseases do not
have such a direct cause-and-effect relationship. Multiple
factors including diet, exercise, smoking, weight, envi-
ronment, and ethnicity affect whether or not an individual
will progress to disease. Still, some companies make
unrealistic claims about their ability to predict future dis-
ease risk from genetic information obtained from a pa-
tient’s buccal swab. Some claims border on scientific
fraud. State, federal, and professional regulatory bodies
are right to work to protect the public. It is the nature of
regulation, however, that it has difficulty “splitting hairs;”
there are labs out there that produce quality results and
labs that do not.
Lab test results, genetic or otherwise, should only be
provided if generated using a U.S. Food and Drug Admin-
istration approved/cleared test or developed and validated
appropriately as a Laboratory Developed Test performed
in a Clinical Laboratory Improvement Amendments-certi-
fied laboratory. In part, this means test results must be
provided in the context of clinical validity. “Labs” that fly
under this regulatory radar (and we use quotes because
that’s all they are, not true, bona fide clinical labs) do not
call what they do ‘testing,’ and instead use euphemisms
to avoid appropriate regulation. Because the companies
cannot make diagnoses, the final report focuses on ques-
tionable statistics and recommends changes in lifestyles,
eating habits, etc—the same kind of generic advice freely
doled out by family members, neighbors, and friends.
This sort of commercial opportunism is at best problem-
atic, at worst, malpractice—and has the potential to re-
flect badly on what bona fide molecular geneticists and
pathologists practice professionally. The public may not
be equipped to differentiate good labs from bad or good
information from bad; regulators may be “handcuffed” from
differentiating labs when they apply new regulations.
Disclaimer forms that must be completed before DTC
genetic testing should send a very strong warning to
consumers who may be spending hundreds or thou-
sands of dollars for information that may or may not be
correct, may or may not be interpreted appropriately or in
context, and may or may not be applicable, or even
necessary. On the other hand, there are many fine “DTC
labs” in the marketplace that provide interesting informa-
tion to those who choose to afford it, thus satisfying
individual curiosity. In actuality, genetic understanding
may stimulate reading about and interest in genomics
and its promise. Knowledge also helps patients cope,
moves clinical trials forward, spurs fundraising, and leads
to conversation. As long as individuals eventually bring
their physicians into the discussion, then harm is averted
and care is enhanced.
Final Thoughts
Direct-to-consumer genomic testing is here. With advances
in technology, the completion of the sequencing of the
human genome, and the pressures of capitalism, its arrival
was inevitable. With the Genetic Information Non-discrimi-
nation Act as the “law of the land,” we should be freer than
ever before to seek out genetic information about ourselves.
Are there some snake oil salesmen out there? Maybe. Are
there also responsible, professional enterprises providing
well-intentioned, appropriately communicated information
to consumers? Certainly. Is the information of value, and is
it worth the asking price? The marketplace will settle this
question long before we diagnosticians reach a consensus
or regulators define jurisdiction. In the meantime, it is the
consumer’s responsibility to exercise caution to avoid be-
coming a victim of marketing ploys that prey on humanity’s
innate curiosity and fears.
The French philosopher Voltaire long ago made a point
highly relevant to this debate. He famously wrote, “I disap-
prove of what you say, but I will defend to the death your
right to say it.” As molecular diagnosticians and physi-
cians,5 we may (or may not) agree with the dissemination of
genomic information directly to consumers without physi-
cians as middlemen, but we will betray our convictions if we
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hinder the consumer’s right to acquire it. Indeed, we ad-
vance our own standing and reputation if we both assist the
marketplace by providing guidelines and educate the pub-
lic in the proper use of genomic information. As clinicians
and diagnosticians, we have a responsibility to exercise our
influence for the enhancement of patient health.
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